Back to today’s briefing

Story perspectives

FDA Approves Generic Mifepristone, Sparking Controversy and Criticism

10/2/2025

48 6 Full Breakdown

Summary

Story summary

The FDA approved Evita Solutions' generic mifepristone on October 2, 2025, amid safety reviews led by Health Secretary Robert F. Kennedy Jr. Evita Solutions says the move expands access to abortion care.
Critics, including Sen. Josh Hawley, call the decision reckless.
Pro-life advocates warn the approval will increase harm to women and unborn children and urge reinstating restrictions.

History

Historical Context

The 1973 Roe v. Wade decision legalized abortion in the U.S., establishing a significant precedent for reproductive rights. In 2000, the FDA approved mifepristone, leading to over 1.5 million prescriptions by 2020. The recent approval of a generic version by Evita Solutions highlights ongoing debates about abortion access, reflecting the enduring conflict between pro-choice and pro-life advocates in American society.

1 of 2

Story summary

The FDA approved Evita Solutions' generic mifepristone on October 2, 2025, amid safety reviews led by Health Secretary Robert F. Kennedy Jr. Evita Solutions says the move expands access to abortion care.
Critics, including Sen. Josh Hawley, call the decision reckless.
Pro-life advocates warn the approval will increase harm to women and unborn children and urge reinstating restrictions.

1 / 2